Navigation Links
Bacterin International Sets Third Quarter 2011 Conference Call for Thursday, November 10, 2011 at 4:30 p.m. ET
Date:10/17/2011

BELGRADE, Mont., Oct. 17, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will hold a conference call on Thursday, November 10, 2011 at 4:30 p.m. Eastern time to discuss results for the third quarter ended September 30, 2011. Financial results will be issued in a press release after the close of the market on the same day.

Bacterin's management will host the presentation, followed by a question and answer period.

Date: Thursday, November 10, 2011
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-877-941-8416
International: 1-480-629-9808
Conference ID#: 4481621

The conference call will be broadcast simultaneously and available for replay here and at the investor section of the company's Web site at www.bacterin.com.

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.

A replay of the call will be available after 7:30 p.m. Eastern time on the same day and until December 10, 2011:

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay pin number: 4481621

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
2. Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter
3. Bacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank
4. Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET
5. Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes
6. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
7. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
8. Bacterin International Holdings Launches Third Biologic Scaffold
9. Bacterin International Holdings, Inc. Schedules Conference Call to Present Fourth Quarter and Full Year 2010 Financial Results
10. Bacterin International Holdings, Inc. Receives Approval for Listing on NYSE Amex
11. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)... 2017 Invivotek, LLC, a Genesis Biotechnology Group ... pharmacology contract research organization (CRO), announced the completion ... expanded preclinical research facility in Hamilton, New ... renewable energy source to reduce costs and lessen the ... Genesis Solar Farm follows Invivotek,s recent expansion from a ...
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... receive the RealSelf 100 Award, a prestigious award honoring the top influencers on ... to find and connect with doctors and clinics. , In 2016, more than ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, Inc., ... and hazardous and non-hazardous materials announced today the acquisition of privately owned ... add four additional processing facilities and a vast array of additional technologies, services, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
Breaking Medicine News(10 mins):